BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 94 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,754 | -65.5% | 4,646 | -9.1% | 0.01% | -65.0% |
| Q2 2023 | $34,033 | -65.6% | 5,110 | -3.6% | 0.02% | -63.0% |
| Q1 2023 | $98,879 | -37.2% | 5,299 | -27.7% | 0.05% | -34.1% |
| Q4 2022 | $157,513 | +17.5% | 7,333 | -35.5% | 0.08% | +54.7% |
| Q3 2022 | $134,000 | -10.1% | 11,365 | +0.7% | 0.05% | -3.6% |
| Q2 2022 | $149,000 | -7.5% | 11,284 | +46.3% | 0.06% | -23.6% |
| Q1 2022 | $161,000 | -3.0% | 7,713 | -5.5% | 0.07% | +14.3% |
| Q4 2021 | $166,000 | -1.2% | 8,164 | +47.1% | 0.06% | -14.9% |
| Q3 2021 | $168,000 | -0.6% | 5,549 | -4.8% | 0.07% | +7.2% |
| Q2 2021 | $169,000 | -39.6% | 5,831 | -10.1% | 0.07% | -41.5% |
| Q1 2021 | $280,000 | -4.8% | 6,486 | +1.9% | 0.12% | -3.3% |
| Q4 2020 | $294,000 | +4.6% | 6,364 | -1.9% | 0.12% | -17.0% |
| Q3 2020 | $281,000 | -28.1% | 6,484 | -12.0% | 0.15% | -20.5% |
| Q2 2020 | $391,000 | – | 7,372 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |